We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Prostrakan | LSE:PSK | London | Ordinary Share | GB00B09STF21 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 129.625 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 129.625 | GBX |
Prostrakan (PSK) Share Charts1 Year Prostrakan Chart |
|
1 Month Prostrakan Chart |
Intraday Prostrakan Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 25/3/2011 17:26 by diamondsales It's gone very quiet, but it could be the lull before the storm! I've topped up my CFD a bit today at 130.75p. OK, I'll lose a bit on this top-up if only the 130p offer goes ahead but my guess is that a higher offer will come in. The third alternative (meaning no offers in the end) doesn't bother me 'cos I believe PSK will prove to be be worth considerably more in the next twelve months anyway. |
Posted at 17/3/2011 08:14 by spool I read the results as extremely positive, Dr Totten's forecast of profitability would have been comfortably met had PSK not been let down by the US partner, very unfortunate all in all for him, however it is quite clear that PSK is on the cusp of being a highly profitable company and I suspect that it would have been better for the small PI's in the med/long term had the takeover not been approved, hopefully interested parties will scupper the current offer sooner rather than later.regards spool |
Posted at 09/3/2011 17:04 by diamondsales What's going on may just be poker. If a higher bid is being prepared the last thing they will do is to make it obvious. Poker faces all round. At close on the Friday before the 130p bid the spread was very wide. That in itself was enough to deter buyers of the shares. A loss-making company, never paid a dividend, a wide spread? Stay clear, would be the normal market reaction, when in reality the share price was about to jump... A higher bid looks an odds on play but nothing is guaranteed. Worst way, if the 130p bid folds and nothing else comes in, I'm happy long term with my shares, accumulated from 63 pence up to 90 odd pence. |
Posted at 07/3/2011 11:14 by diamondsales The fact that PSK is steadily trading at 132.50-132.75 suggests that the market doesn't believe it's game over at 130p. A sector expert tells me another bid is anticipated. It won't be life changing but it's worth holding if you're in for less than 130p. |
Posted at 07/3/2011 08:40 by spool Cheers Steph, hope you are right! I am still holding on the basis that the potential upside is much greater than the current price versus the offer.regards, spool |
Posted at 21/2/2011 14:26 by craigends Reckon this is at least worth 10p more -hopefully let play commence.Either way it is closure time for PSK and good exit price for me. |
Posted at 13/1/2011 08:14 by spool Any buyer with a notifiable interest has a specified amount of time to declare an increase or decrease in their holding, Norgine probably purchased the shares whilst they were in the 90p range and due to the holiday period etc the 5th would be on or around the period at which they had to declare the change.There is a lot of interest in this share at present due mainly to the takeover talks, I think further positive news on income stream will see it rocket, as this will see PSK become a viable stand alone or the suitors will make an offer too good to refuse. Regards, spool |
Posted at 10/1/2011 09:45 by youwould Key quote from their press release today, aside from the excellent growth in 2010...."ProStrakan today announces that it has received approval from the FDA for Abstral (fentanyl) Sublingual Tablets.......Abstra Abstral is the first product to be approved in the US with the FDA mandated class-wide Risk Evaluation and Mitigation Strategy ("REMS") for transmucosal immediate release fentanyl products. The Abstral REMS allows appropriate prescriptions to be filled at retail pharmacies as well as providing access to Abstral within hospitals" This is HUGE news - The US market have been desperate for a product like this for a long time. Abstral is far better than its closest rival Effentora which sells many millions $'s and is not even promoted currently..... with the salesforce that Prostrkan have trained and ready in the US Abstral is going to really fly.... and we still have news about Sancuso manufacturing, a new CEO and potential takeover to increase the share price further. Sit tight on this one - the only way is up, up, up...... |
Posted at 30/12/2010 07:15 by stephanie_m Excellent Newss RNS Number : 6880Y ProStrakan Group plc 30 December 2010 ProStrakan Group plc ProStrakan's FORTESTA Receives US FDA Approval Galashiels, UK. 30th December, 2010 - ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that approval has been received from the US Food and Drug Administration (FDA) for FORTESTA(TM) (testosterone) Gel. Endo Pharmaceuticals Inc. (NASDAQ: ENDP), with whom ProStrakan has partnered for this product in the US, now plans to launch FORTESTA in early 2011. FDA approval of FORTESTA has now triggered an approval milestone payment from Endo of $12.5m. ProStrakan plans to include further technical details concerning this approval in its market update scheduled for early January 2011. General Meeting On 16th December, ProStrakan announced that it plans to enter into a new strategic relationship with Paladin Labs Inc. ("Paladin") in which Paladin will acquire, by way of assignment, ProStrakan's existing GBP50m secured debt facility, with the addition of certain conversion rights, and will be granted an exclusive licence to ProStrakan's products for certain emerging territories ("the Proposals"). A shareholder circular has been sent to the Group's shareholders as the Proposals are conditional upon, amongst other things, the approval of ProStrakan's shareholders being obtained at a General Meeting to be held on 7th January 2011. Shareholders should note that, in relation to the option described in the announcement and circular referred to above, in terms of which the Company could require Paladin to purchase its Xomolix product (and related intellectual property and other assets) at a fixed price based on a multiple of 12 months' net sales, now that FDA approval of FORTESTA has been secured, this option will lapse unexercised. Offer Update As announced by the Company on 15th November 2010, the Board has received expressions of interest in the Company and its assets which it is evaluating. The process of evaluating these expressions of interest is at a preliminary stage and the Company cannot provide any further information in relation to a potential offeror or offerors or any information in relation to any potential offer. Enquiries: ProStrakan +44 (0) 7803 970103 Callum Spreng, Corporate Communications -------------------- Brunswick Group +44 (0) 20 7404 5959 -------------------- Jon Coles / Justine McIlroy -------------------- This information is provided by RNS The company news service from the London Stock Exchange END |
Posted at 15/11/2010 14:34 by craigends Will they buy this time -reckon debt is main driver for PSK to accept -hopefully at higher share price than market showing - on the day possible bid announced a relatively small rise! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
